Skip to main content
. 2018 Aug 6;9:3115. doi: 10.1038/s41467-018-05370-7

Fig. 8.

Fig. 8

TRPS1 is needed for efficient tumour growth in vivo. a Western blot for TRPS1 in 4T1 cells infected with two different shRNAs targeting TRPS1 or a non-targeting shRen (Renilla) control, respectively. Serial dilutions (lanes 1–3) of the shRen control are loaded to demonstrate the knockdown efficiency. b Tumour growth of 4T1-derived tumours orthotopically transplanted into the mammary gland of BALB/C mice. Tumour size was monitored after the indicated times of injection. Data are presented as means ± s.e.m. Two-way ANOVA test. c The tumour weight of the 4T1-derived tumours was determined 23 days after transplantation. One-way ANOVA test. d Photos of 4T1-derived tumours 23 days after transplantation. Scale bar = 1 cm. e Representative images of IHC stainings for CD3-positive cells (T cells) in sections of the 4T1-derived tumours. Scale bar = 50 μm. f Quantification of (k). Error bars represent s.e.m. One-way ANOVA test. g Expression of signature gene sets for natural killers (NK), cytotoxic T cells (CD8) and helper T cells (CD4) were sorted based on TRPS1 activity in breast cancer patients. Spearman rank correlation test